Download Principal Investigator Dr Martin Rutter Address

Principal Investigator
Dr Martin Rutter
Address
University of Manchester, Manchester Diabetes Centre, 193 Hathersage
Road, Manchester M13 0JE. United Kingdom
Lead Collaborators:
1.
2.
3.
4.
5.
Dr Ioanna Tzoulaki
Professor Nilesh Samani
Professor Naveed Sattar
Dr Jack Bowden
Mr Seamus Harrison
Collaborating Institutions and Addresses:
1. Imperial College London, Epidemiology and Biostatistics, Norfolk Place, London W2
1PG. United Kingdom.
2. University of Leicester, Department of Cardiovascular Sciences, Clinical Sciences
Wing, Glenfield Hospital, Groby Road, Leicester LE3 9QP. United Kingdom.
3. University of Glasgow, Cardiovascular and Medical Sciences, 126 University Place,
Glasgow G12 8TA. United Kingdom.
4. University of Bristol, MRC Integrative Epidemiology Unit, Oakfield House, Oakfield
Grove, Bristol BS8 2BN. United Kingdom.
5. University of Cambridge, Cardiovascular Epidemiology Unit, Strangeways Research
Laboratory, Wort’s Causeway, Cambridge CB1 8RN. United Kingdom.
Summary of research:
Arterial stiffness, cardiovascular disease, pathogenesis,prognosis
Application Lay Summary:
1a: We will:
1. Identify genes and risk factors related to arterial stiffness (AS) assessed using
a) the PulseTrace device (PTD) and b) magnetic resonance imaging (MRI);
2. Identify genes and risk factors predicting worsening PTD-AS and identify if
PTD-AS predicts worsening blood pressure;
3. Use genetic information to explore the direction of causal relationships linking
arterial stiffness, hypertension and cardiovascular events.
4. Examine whether AS assessed by PTD or MRI predicts cardiovascular events
beyond that achieved using traditional risk factors.
5. Assess whether particular antihypertensive drug classes are associated with
preferential clinical benefits in relation to arterial stiffness.
1b: Arterial stiffness is an independent predictor of cardiovascular events that
can be measured noninvasively using the PulseTrace device (PTD) and by
assessing aortic distensibility and pulse wave velocity using magnetic resonance
imaging (MRI).
The main aim of this research is to better understand the molecular mechanisms
leading to arterial stiffness. By understanding these mechanisms, appropriate
treatments can be developed that could reduce the risk of heart attacks and
strokes especially in patients predisposed to arterial stiffness such as those with
diabetes.
Cardiovascular disease has major health, economic and societal impacts so there
could be widespread benefits from this research.
1c: Routinely collected UK Biobank data from baseline, follow-up and imaging
examinations and conventional statistical methods including genome-wide
association studies will be used to:
a) Identify genes and traditional cardiovascular risk factors related to arterial
stiffness (AS) and worsening of AS;
b) Assess whether AS has a causal role in cardiovascular events (Mendelian
randomisation studies) and incident hypertension (traditional epidemiology);
c). Assess whether AS assessed by PTD and MRI predict cardiovascular events
beyond that achieved using traditional risk factors;[1,2]
d) Relate antihypertensive drug class used by participants to arterial stiffness,
blood pressure levels and CVD events.
1d: We will study the subsets - people with:
a) PulseTrace device (PTD)-measured arterial stiffness (AS) data (n~200K)
b) Magnetic Resonance Imaging (MRI) derived data on aortic distensibility/pulse
wave velocity (n~100K)
c) Manchester-based participants with baseline and 4-year follow-up data who
had AS assessed by PTD or MRI at any time (~10K).
These participants will be involved in cross-sectional, prospective, genome-wide
association and Mendelian randomisation studies.